SciBase Secures Major US Payer Coverage and Aims for Global Dominance in Skin Assessment #USA #Stockholm #dermatology #Nevisense #SciBase
@newsen.bsky.social
@newsen.bsky.socialSciBase Secures Major US Payer Coverage and Aims for Global Dominance in Skin Assessment #USA #Stockholm #dermatology #Nevisense #SciBase
@newsen.bsky.socialSciBase Achieves Historic Coverage with Highmark, Transforming Dermatology Access #United_States #Stockholm #Nevisense #SciBase #Highmark
@newsen.bsky.socialSciBase Achieves Landmark Payer Coverage with Highmark, Advancing U.S. Expansion #Sweden #Stockholm #Nevisense #SciBase #Highmark
@newsen.bsky.socialSciBase Successfully Registers Rights Issue and Share Conversion in Landmark Decision #Sweden #Stockholm #Nevisense #SciBase #BTA
@newsen.bsky.socialSciBase Successfully Completes Rights Issue with Strong Investor Support and $57.5 Million Raised #Sweden #Stockholm #Nevisense #SciBase #Bergs_Securities
@newsen.bsky.socialSciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million #Sweden #Stockholm #Nevisense #SciBase #Rights_Issue
@newsen.bsky.socialSciBase Strengthens Collaboration with Castle Biosciences Through Additional Order #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences
@newsen.bsky.socialSciBase Moves to Strengthen Position with SEK 58 Million Rights Issue Strategy #Sweden #Stockholm #Nevisense #SciBase #Bergs_Securities